In HCC, LASP1 is further regulated by urokinase plasminogen activator (uPA), whose expression is an unfavorable prognostic factor and a therapeutic target in HCC: LASP1 is downregulated upon uPA inhibition and conversely uPA upregulation increases LASP1 expression and affects cell motility. This evidence concerns the gene PLAU and hepatocellular carcinoma.